<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750616</url>
  </required_header>
  <id_info>
    <org_study_id>1620125</org_study_id>
    <nct_id>NCT04750616</nct_id>
  </id_info>
  <brief_title>NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial</brief_title>
  <acronym>NACAM</acronym>
  <official_title>NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury (NACAM) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for&#xD;
      the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a single-center, randomized, double-blind placebo-controlled Trial of Nam&#xD;
      versus placebo in patients undergoing on-pump cardiac surgery. After screening and&#xD;
      enrollment, patients will be stratified according to CKD status (eGFR&lt;45 ml/min/m2) and&#xD;
      surgical site and randomized in a 1:1 manner to receive either Nam 3 grams or placebo on the&#xD;
      day of surgery and post-surgical days one and two.&#xD;
&#xD;
      The overall trial duration is planned for 42 months, consisting of 39 months of active&#xD;
      recruitment and treatment period and three months of follow-up from the last patient&#xD;
      enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Troponin T AUC</measure>
    <time_frame>From baseline to three days after surgery</time_frame>
    <description>Troponin T AUC, composed of single daily serum measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean difference in uQuin/Tryp ratio AUC</measure>
    <time_frame>From baseline to three days after surgery</time_frame>
    <description>Mean difference in uQuin/Tryp ratio AUC composed of single daily serum measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean difference in eGFR</measure>
    <time_frame>From baseline through day 5.</time_frame>
    <description>Mean difference in eGFR (CKD-EPI formula)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with the following Adverse Events and Serious Adverse Events</measure>
    <time_frame>From baseline through day 90</time_frame>
    <description>Postoperative dysrhythmias&#xD;
Postoperative re-hospitalization.&#xD;
Heart failure&#xD;
Surgical wound infection&#xD;
Transfusion requiring perioperative bleed&#xD;
Post-surgical deep vein thrombosis and pulmonary emboli&#xD;
Nosocomial infection&#xD;
Nausea and vomiting&#xD;
Adverse events leading to treatment discontinuation&#xD;
Perioperative liver injury (x2 upper normal-limit)&#xD;
Post-operative thrombosis and pulmonary emboli&#xD;
Impairment of renal function (KDIGO AKI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of index hospital stay.</measure>
    <time_frame>From baseline through day 90</time_frame>
    <description>• Mean length of index hospital stay (days)</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of intensive care unit stay.</measure>
    <time_frame>From baseline through day 90</time_frame>
    <description>• Mean length of intensive care unit stay (days)</description>
  </other_outcome>
  <other_outcome>
    <measure>Perioperative inotropic-score and vasoactive-inotropic score.</measure>
    <time_frame>At 6, 12, 24, and 48 hours post operatively</time_frame>
    <description>• Mean inotropic-score and vasoactive-inotropic score</description>
  </other_outcome>
  <other_outcome>
    <measure>Perioperative fluid volume administration.</measure>
    <time_frame>From baseline through day 2</time_frame>
    <description>• Mean daily perioperative fluid volume administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Perioperative brain-natriuretic peptide AUC</measure>
    <time_frame>From baseline to three days after surgery</time_frame>
    <description>BNP AUC, composed of single daily serum measurements</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <condition>Myocardial Injury</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Oral niacinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacinamide</intervention_name>
    <description>Niacinamide 3 grams on the day of surgery and post-surgical days one and two</description>
    <arm_group_label>Oral niacinamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo on the day of surgery and post-surgical days one and two</description>
    <arm_group_label>Matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Informed consent before any study-related activities.&#xD;
&#xD;
          -  Men or women &gt;18 years of age who are scheduled for non-emergent cardiac surgery&#xD;
             procedures requiring CPB and are at increased risk for surgery-related adverse&#xD;
             cardiovascular outcomes.&#xD;
&#xD;
        Procedures include:&#xD;
&#xD;
          -  CABG&#xD;
&#xD;
          -  Aortic, mitral, tricuspid, or pulmonic valve replacement or repair&#xD;
&#xD;
          -  CABG with aortic, mitral, tricuspid, and/or pulmonic valve replacement&#xD;
&#xD;
        Risk factors for surgery related to adverse cardiovascular outcomes include one or more of&#xD;
        the following:&#xD;
&#xD;
          -  Valve surgery&#xD;
&#xD;
          -  eGFR &lt; 45 ml/min/1.73m2&#xD;
&#xD;
          -  Documented LVEF ≤ 35% within six months before surgery&#xD;
&#xD;
          -  Documented history of heart failure&#xD;
&#xD;
          -  Insulin-requiring diabetes&#xD;
&#xD;
          -  Non-insulin-requiring diabetes and the presence of ≥+2 proteinuria on urinalysis (or&#xD;
             equivalent on urine protein-to-creatinine ratio or urine albumin-to-creatinine ratio)&#xD;
&#xD;
          -  Preoperative anemia (hemoglobin &lt;11g/dl for men and women)&#xD;
&#xD;
          -  History of prior CABG&#xD;
&#xD;
          -  Age ≥65&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Preexisting AKI within seven days before surgery as defined by KDIGO stage ≥1 (serum&#xD;
             creatinine-based)&#xD;
&#xD;
          -  Kidney transplant status&#xD;
&#xD;
          -  Off-pump cardiac surgery&#xD;
&#xD;
          -  ESRD&#xD;
&#xD;
          -  Emergent cardiac surgery&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient enrolled in competing research studies that may affect outcomes&#xD;
&#xD;
          -  Patients held in an institution by legal or official order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ali Poyan Mehr, MD</last_name>
    <phone>4152644750</phone>
    <email>ali.x.poyanmehr@kp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Permanente San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Poyan Mehr, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ahmad Sheikh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Avins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lance Rtherford, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul LaPunzina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

